SRR1516055
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.560
- INFLAMMATORY_RESPONSE+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- TNFA_SIGNALING_VIA_NFKB+0.500
- IL6_JAK_STAT3_SIGNALING+0.490
- E2F_TARGETS+0.470
- ANGIOGENESIS+0.450
- COMPLEMENT+0.390
Top 10 suppressed
- BILE_ACID_METABOLISM-0.280
- PEROXISOME-0.260
- ESTROGEN_RESPONSE_EARLY-0.150
- FATTY_ACID_METABOLISM-0.120
- NOTCH_SIGNALING-0.100
- ESTROGEN_RESPONSE_LATE-0.090
- XENOBIOTIC_METABOLISM-0.060
- ADIPOGENESIS-0.040
- KRAS_SIGNALING_DN-0.040
- UV_RESPONSE_DN+0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516056 | — | — | 0.978 |
| 2 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.933 |
| 3 | SRR29022839 | — | A | 0.927 |
| 4 | TCGA-66-2744-01A-01R-0980-07 | — | cohortA1 | 0.911 |
| 5 | R209 | — | — | 0.908 |
| 6 | R409 | — | — | 0.906 |
| 7 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.904 |
| 8 | s0112234 | — | — | 0.898 |
| 9 | TCGA-ZF-AA58-01A-12R-A42T-07 | — | — | 0.896 |
| 10 | TCGA-XF-A9SM-01A-11R-A42T-07 | — | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.550 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.340 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |